A Study of the Cardiac Effects of Danicopan in Healthy Adults

Study Identifier:
ACH471-013
ClinicalTrials.gov Identifier:
NCT05016206
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: Danicopan
  • Drug: Moxifloxacin-matching Placebo
  • Drug: Danicopan-matching placebo
  • Drug: Moxifloxacin
Date
Jul 2018 - Oct 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: Danicopan
  • Drug: Moxifloxacin-matching Placebo
  • Drug: Danicopan-matching placebo
  • Drug: Moxifloxacin
Date
Jul 2018 - Oct 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information

Protocol Summary

This was a randomized, double-blind, double-dummy, placebo- and positive-controlled, 2-arm (Treatment Arm and Control Arm), parallel study to evaluate the effect of ACH-0144471 (danicopan) on the QT interval in healthy adult participants.

Trial Locations

Location
Status
Location
Clinical Trial Site
Tempe, Arizona, United States, 85283
Status
N/A